---
title: "Weekly Recap | IOVA.US +3.45%, outperforming the S&P 500"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/302952094.md"
description: "Iovance Biotherapeutics (IOVA) added 3.45% this week, closing at $14.09, versus a 0.47% decline for the S&P 500, outperforming by about 3.92 percentage points. The move was choppy: the stock climbed to $14.86 by Tuesday, touched an intraday high of $15.37 on Wednesday, then slipped on Thursday and Friday to end the week at $14.09. Weekly range was 13.26%, with volume running well below recent median levels."
datetime: "2026-10-24T06:31:42.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/302952094.md)
  - [en](https://longbridge.com/en/news/302952094.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/302952094.md)
generator: "portal-rs"
---

# Weekly Recap | IOVA.US +3.45%, outperforming the S&P 500

## The Week

Iovance Biotherapeutics (IOVA) added 3.45% this week, closing at $14.09, versus a 0.47% decline for the S&P 500, outperforming by about 3.92 percentage points. The move was choppy: the stock climbed to $14.86 by Tuesday, touched an intraday high of $15.37 on Wednesday, then slipped on Thursday and Friday to end the week at $14.09. Weekly range was 13.26%, with volume running well below recent median levels. There were no major catalysts; the two news items centred on clinical data for lifileucel.

## Analyst Ratings

Among the 10 firms covering Iovance, 6 rate it buy, 2 over, and 2 hold; the consensus rating is buy. The consensus target sits at $14.40, about 2.2% above the latest close of $14.09. Individual targets range from $7 to $20, showing wide dispersion. Iovance ranks 139 out of 511 in its industry group, in the upper-middle tier.

## The Week Ahead

The macro calendar is busy next week, with durable goods orders, FHFA and Case Shiller home price prints, new home sales, and consumer confidence due on Tuesday. On the corporate side, Iovance reports its fiscal Q3 2026 results on 6 November, so no earnings are expected next week. The ESMO 2026 data on lifileucel plus pembrolizumab in frontline advanced melanoma may continue to draw attention.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [IOVA.US](https://longbridge.com/en/quote/IOVA.US.md)

## Related News & Research

- [Iovance Reports Durable Responses With Lifileucel in Early Soft Tissue Sarcoma Trial](https://longbridge.com/en/news/302279490.md)
- [Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | IOVA Stock News](https://longbridge.com/en/news/302148043.md)
- [AI fever ignites a boom in thematic ETFs as fund managers hunt for their next big hit](https://longbridge.com/en/news/302963080.md)
- [Memory Stocks Are Plummetting. Jensen Huang Says the Bears Have It Wrong.](https://longbridge.com/en/news/302948213.md)
- [Hanseatic Management Services Inc. Buys New Stake in Marvell Technology, Inc. $MRVL](https://longbridge.com/en/news/302958015.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**